BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Noninfectious Uveitis. This report, based on feedback gathered in an on-line survey completed by 72 retinal specialists in June/July 2010, addresses the medical management of noninfectious uveitis (anterior, intermediate, posterior and panuveitis) and referral/co-management patterns between retinal specialists and other specialties.
The study focuses on the use of corticosteroids (topical, systemic, periocular, intravitreal injections and implants, and intravenous) and steroid-sparing drug classes (immunosuppressants, alkylating agents, and biologics) by retinal specialists for the treatment of noninfectious uveitis. In addition to uncovering the attributes that are most important to retinal specialists when choosing therapies to treat non-infectious uveitis, the report delves into physician attitudes and perceptions toward these drug classes, overall advantages and disadvantages, barriers to growth and expected future use of specific products within the drug classes. Promotional activity for Bausch & Lomb's Retisert and Alcon's Durezol and Triesence is also assessed.
Respondents were queried about their awareness of and interest in products in development for noninfectious uveitis including Lux Biosciences' Luveniq, Celgene's apremilast, Eyegate Pharma's EGP-457 and Novartis' AIN-457. Retinal specialists feel that products that are easily managed by general ophthalmologists and those that have the potential for long-term, drug-free remission would go the farthest in filling the greatest unmet needs in the treatment of noninfectious uveitis.
Diet's role in fighting vitiligo highlighted in new research